可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Steering Committee and membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendation for the management of chronic heart failure[J].Am J Cardiol,1999,83:2A-38A.
[2] Schrier R,Abraham W. Hormones and hemodynamics in heart failure[J].N Engl J Med,1999,341:577-585.
[3] Packer M,Bristow M,Cohn J,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart faulure [J].N Engl J Med,1996,334:1349-1355.
[4] MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) [J]. Lancet,1999,353:2001-2007.
[5] Hjalmarson A,Goldstein S,Fagerberg B,et al. Effects of controlled-release metoprolol on total mortality,hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)[J].JAMA,2000,283:1295-1302.
[6] CIBIS-Ⅱinvestigators and committees. The Cardiac Insufficiency Bisoprolol StudyⅡ(CIBIS-Ⅱ): a randomized trial [J].Lancet,1999,353:9-13.
[7] Cardinale V,Chi J. Drug Topics red book[M]. Montvale,NJ: Medical Economics, 1999.
[8] Bleske BE,Glibert EM,Munger MA. Carvedilol:therapeutic application and practice guidelines[J].Pharmacotherapy,1998,18:729-737.
[9] 洪中立.慢性心力衰竭治疗和评估的新进展[J].心脏杂志,2001,13(5):406.
[10] Bonet S,Agusti A,Arnau JM,et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients′characteristics:a meta-analysis of clinical trails[J].Arch Intern Med,2000,160:621-627.